The ink on the DOJ’s rescheduling announcement was barely dry before Capitol Hill started working to undo it. Here’s a breakdown of the political fight brewing over cannabis’ new federal status — and what it means if the opposition actually wins.
One week after the DOJ’s historic April 23rd announcement placing medical cannabis in Schedule III of the Controlled Substances Act, a House appropriations subcommittee voted to block it. Not debate it. Not slow it down. Block it — using one of the oldest and most reliable tools in the congressional obstruction playbook.
If you’ve been following this series — what the order does, what it means for patients, and what it means for businesses — you already know that the rescheduling action came with significant caveats and unresolved legal questions. Congressional opposition is the biggest of those questions, and it deserves its own honest breakdown.
This isn’t doom and gloom — similar efforts have failed before, and there are structural reasons they’re hard to execute. The threat is real. The players are motivated. And the industry needs to understand what it’s up against.
The Vote That Flew Under the Radar
On April 30, 2026 — exactly one week after the rescheduling announcement — the House Appropriations Subcommittee on Commerce, Justice, Science and Related Agencies voted 8-6 along party lines to advance a spending bill containing language that would prohibit federal officials from using any appropriated funds to reschedule marijuana or remove it from the CSA schedules altogether.
Full coverage from Marijuana Moment here.
The vote wasn’t close, it wasn’t bipartisan, and it wasn’t subtle. Eight Republicans voted to include the blocking language. Six Democrats voted against it.
The bill now moves forward in the appropriations process — which is a long way from becoming law, but it’s further than a lot of people realize.
What makes this particularly notable is the timing.
The Trump administration actually drove this rescheduling action. Acting AG Todd Blanche signed the order at the direction of a Trump Executive Order from December 2025. Congressional Republicans voting to block it aren’t just opposing cannabis reform; they’re openly defying the president’s own policy directive.
That’s a fracture worth paying attention to.
The Republican Party doesn’t have a unified position on cannabis rescheduling — and that internal split is both the industry’s biggest vulnerability and its most interesting political opening right now.
Meet the Lawmakers Trying to Block It
The Fresh Toast did a solid job naming names here, so let’s be direct about who’s driving this effort:
- Speaker Mike Johnson (R-LA) — Has been consistently opposed to cannabis liberalization and has allowed anti-rescheduling language to advance under his speakership.
- House Appropriations Committee Chair Tom Cole (R-OK) — The committee leader whose fingerprints are on the spending bill that contains the blocking rider.
- Senator James Lankford (R-OK) — One of the most vocal Senate opponents of rescheduling, has pushed to attach blocking language on the Senate side as well.
- Senator Ted Budd (R-NC) — Has been active in opposition efforts, notable given that North Carolina is actively discussing medical cannabis legalization in the wake of the rescheduling announcement.
What these lawmakers share, broadly: deep ties to socially conservative constituencies, long records of opposing cannabis reform, and a willingness to use procedural tools rather than direct legislation to accomplish their goals. None of them are introducing a bill to re-schedule cannabis back to Schedule I.
They don’t need to — if they can starve the rescheduling process of federal funding, the effect is similar.
It’s also worth noting who isn’t in this fight: a meaningful number of Republican lawmakers have either stayed quiet or signaled openness to rescheduling, particularly those from states with established medical cannabis programs or significant cannabis industry economic footprints. The opposition is loud, but it’s no longer the Republican party at large.
The Appropriations Rider Playbook: How It Works and Why It (Usually) Fails
For readers who aren’t as well versed in congressional procedures — and honestly, why would you be? — here’s a quick explainer on how the appropriations rider strategy works and why it’s both effective and limited.
An appropriations rider is a policy provision attached to a spending bill. Passing standalone legislation requires majority votes in both chambers, debate, amendment, and eventually presidential signature. However, a rider like this one moves through the process as part of a larger package, tucked into a must-pass budget bill.
So, if the overall spending bill passes, the rider becomes law even if it couldn’t have realistically passed on its own merits.
The cannabis industry has actually benefited from this strategy before — the Rohrabacher-Blumenauer amendment (also called the Joyce amendment), has protected state medical cannabis programs from federal prosecution since 2014. The amendment has impressively survived as an appropriations rider for over a decade.
Now, the opponents of rescheduling are hoping to use the same playbook in reverse.
So why do riders for controversial matters usually fail? A few reasons:
- Riders in the House often don’t survive the Senate, where the filibuster and bipartisan negotiations often strip out the most contentious policy provisions before a final bill passes.
- Government funding bills frequently fail to pass on time entirely. So, to get something passed quickly, this usually leads to carrying over existing policy without enacting new riders.
- The Trump administration’s explicit support for this rescheduling action creates unusual political pressure on Republican senators to not openly defy the president on a budget vote.
- The immediate protections from the April 23rd order — which took effect upon signing — may not be reversible by a prospective funding prohibition, creating a legal gray zone that would no doubt take additional litigation to resolve.
A passed rider could halt the June 29 broader rescheduling hearing and freeze any future DEA action. It’s much less clear whether it could retroactively undo protections that went into effect on April 23rd — that question would land in court.
What Happens If It Actually Passes This Time?
Let’s play it out, because the industry deserves a clear-eyed look at the downside scenario.
If the appropriations rider language survives into an enacted spending bill, the most immediate impact would be on the June 29 administrative hearing that was announced alongside the April 23rd order. Designed to consider the broader rescheduling of all marijuana — not just state-licensed medical cannabis — from Schedule I to Schedule III, the hearing is the next step in the process.
The DEA registration portal and the application process for medical operators could also be affected — if federal employees can’t use appropriated funds to administer the program, the entire registration framework could go into limbo. Early applicants like Trulieve and other MSOs that moved quickly to register would be in more legal uncertainty about what their registration status actually means than they already are.
The 280E relief question is the most legally complex piece of the puzzle.
As Harris Sliwoski has noted, the rescheduling order itself — not subsequent DEA administration — is what triggered the change in 280E applicability. Whether a funding rider can effectively reverse a change to how the IRS interprets an existing tax code provision is genuinely unsettled and uncertain legal territory. Expect litigation on that specific question if the rider passes.
The least likely outcome: a clean, complete reversal of everything that happened on April 23rd.
The most likely outcome if the rider passes: a prolonged period of legal uncertainty that chills industry investors, freezes the broader rescheduling process, and leaves operators in a confusing middle ground where the protections are technically in place but being practically contested.
That’s not a good outcome. It’s also not the worst one. The industry has been operating in legal gray zones for decades — this would be a new and particularly frustrating one, but it wouldn’t be uncharted territory by any stretch of the imagination.
The Irony: It’s The Same Bill That Protects State Medical Programs
And like the rest of this series so far, here’s a look at the part of this story that deserves way more attention than it’s getting (which might even be none).
The same House spending bill that contains this anti-rescheduling rider also includes an updated version of the Rohrabacher-Blumenauer amendment.
Remember, I mentioned it earlier? It’s the longstanding provision that prohibits the DOJ from spending federal funds to interfere with state medical cannabis programs. And this version has been expanded to include Nebraska for the first time following Nebraska voters’ approval of medical cannabis in the 2024 election.
Let that sink in for a second.
The same bill that Republican appropriators are using to try to kill federal rescheduling also quietly extends the most important existing federal protection for state medical cannabis programs to a new state. They’re blocking progress with one hand and acknowledging the political reality of medical cannabis with the other.
This isn’t hypocrisy so much as it’s a window into where the Republican caucus really stands on cannabis: broadly unwilling to advance federal reform, broadly unwilling to directly attack state medical programs that their own constituents depend on (and deeply split on everything in between).
The political fight over rescheduling isn’t really about whether cannabis has medical value — that argument is over and the anti-rescheduling side knows it. It’s about who controls the regulatory framework, and whether the federal government moves toward normalization on a timeline these lawmakers can’t control.
What This Means for the Industry Right Now
Watch the appropriations process closely — not just for cannabis-specific headlines, but for the broader government funding timeline. If Congress fails to pass a full spending bill (which is increasingly common), a continuing resolution that punts the budget fight could either preserve the status quo or carry the rider forward depending on how it’s written.
Watch the June 29 hearing. If it proceeds as scheduled, that’s a signal that the rider strategy hasn’t gained enough traction to pause the process. On the other hand, delaying or canceling the hearing would be early warning signs that the opposition is making headway.
And watch the SAM litigation. The legal challenge to the rescheduling order’s underlying authority — separate from the congressional fight — is the wildcard that could affect everything regardless of what happens on the appropriations side.
The industry has been here before: meaningful progress followed immediately by organized resistance.
The difference this time is that the executive branch is nominally on the same side as reform, which creates a political dynamic that’s genuinely new. Whether that’s enough to hold off a determined congressional minority is the question that’s going to define the next six months.
Up next — and last — in this series: the argument that Schedule III is the wrong conversation entirely. Cannabis doesn’t belong in the CSA at all, and the evidence for a completely different regulatory model has been sitting in plain sight for years. That’s coming soon to ATC.
